Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that it has entered into a strategic advisory agreement with H.C. Wainwright & Co., LLC ("Wainwright").
Pursuant to this agreement, Wainwright will assist Lakewood-Amedex in exploring various licensing, M&A, and other strategic endeavors for both existing pipeline products as well as the company's platform technology within the current competitive landscape.
Lakewood-Amedex President and CEO, Steve Parkinson, remarked, "We are excited to be working with H.C. Wainwright & Co., LLC, a well-known and highly respected New York investment bank. As we prepare to advance our lead bisphosphocin, Nu-2, into clinical trials, we believe that this is an opportune time to engage experienced advisors to help us explore and maximize the value of potential collaborations and relationships with other firms and potential investors in the space."
Study focuses on COPD progression in younger populations